Cardiology

In the CLEAR Outcomes trial, bempedoic acid was associated with a 20% reduction in relative risk for total cardiovascular events, with further analysis shining light on the effects of specific types of events.

An analysis of the RAFT trial showed patients with heart failure treated with CRT-D experienced continued survival benefits during a median of nearly 14 years of follow-up.

Prescribing phosphodiesterase type 5 inhibitors and nitrates together may increase the risk of morbidity and mortality for patients over time.

This cardiology case report from Brady Pregerson, MD, features a man in his early 60s with no known medical history presenting with chest pain radiating to both armpits and anterior neck, but not to the back. How would you react?

Dr Taub, Dr Patel, and Dr Kohli look ahead to the future of the management of cardiovascular risk and hyperlipidemia

Cardiologists discuss how to select the right treatment for your patient with hyperlipidemia

Expert cardiologists discuss the recent clinical trials results of the CLEAR-OUTCOMES trial and thee sub analysis on the inflammatory marker hcCRP.

A multidisciplinary panel assembled by the Society for Cardiovascular Angiography & Interventions examined and supported the role of intravascular ultrasounds in lower extremity revascularization procedures.

Randomized trial data shows colchicine administered following catheter ablation did not reduce atrial arrhythmia recurrence or associated clinical events.

Serum-COMP was linked to an increased risk of both cardiovascular disease and coronary artery disease.

Applied Therapeutics announced topline results from ARISE-HF on January 04, 2023 and plans to present full results at an upcoming medical conference.

A new study identified T1D as a risk factor associated with nearly all subtypes of CHD, whereas overweight was associated only with certain defect types.

Dr Kohli gives an overview of the mechanisms of action of non-statin agents for the management of hyperlipidemia.

Expert cardiologists discuss the cumulative burden of an elevated cholesterol over time.

Our cardiology month in review spotlights our most popular cardiology-centric content from the month of December 2023. The list includes topline data from SEQUOIA-HCM, new data on the impact of structural racism on chronic health conditions, and more!

Post hoc analysis of STRONG-HF trial underscores benefits of higher guideline-directed medical therapy doses in acute heart failure, showing lower rates of death or readmission at 6 months with more rapid uptitration.

On December 27, 2023, Cytokinetics announced positive topline results from the phase 3 SEQUOIA-HCM trial evaluating aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy

This cardiology case report from Brady Pregerson, MD, features a man in his mid-30s brought by ambulance after 3-4 days of peripheral edema and generalized weakness after a missed dialysis appointment. Can you determine the correct diagnosis?

A new study is raising awareness around the effects of structural racism on the prevalence of chronic health conditions.

Sex-based differences in hypertrophic cardiomyopathy outcomes reveal higher risks for women, including all-cause mortality.

Among adults in middle- to high-income nations, awareness of diabetes as a cardiovascular risk factor remains a persistent issue.

Califf joins HCPLive to share perspective on AI, gene and cell therapy development, COVID-19, food and substance regulation, maternal and infant health, weight loss intervention, and more.

Following years of concerns about the stigmatization and inaccurate etiology of nonalcoholic fatty liver disease nomenclature, 2023 finally saw revised terminology for liver disease with the implementation of metabolic dysfunction-associated steatotic liver disease.

Presented at ASH 2023, findings of a new study showed patients with sickle cell disease and venous thromboembolism have longitudinal worsening of left ventricular diastolic and right-sided cardiac function.

Phase 3 data show patients with obesity who maintained tirzepatide from weeks 36 to 88 continued significant weight loss versus patients switched to placebo.

Findings of a new study suggest COVID-19 does not serve as risk factor for the development of VTE in pediatric cancer patients.

An overview of the journey and significant events of 2023 that have catapulted semaglutide from a type 2 diabetes agent to the topic of discussions among circles across healthcare and beyond.

Our November 2023 month in review for cardiology features highlights from AHA 2023, new atrial fibrillation guidelines, a pair of historic approvals from the FDA, and more!

We kick off our annual recap series with some reflections from our expert advisory board, on topics ranging from AI and cell therapies, to semaglutide and RSV vaccines.

Released on Nov. 30, 2023, the new AFib guidance from the ACC/AHA contains update recommendations for early and aggressive rhythm control, wearables, left atrial appendage occlusion, and more.